CSF biomarker analysis of ABCA7 mutation carriers suggests altered APP processing and reduced inflammatory response

Table 2 Associations between CSF biomarkers and ABCA7 mutation status in the Aβ-positive AD cohort

	Mutation carriers vs non-carriers
	All			PTC carriers			Expansion carriers
	β	SE	P-value	β	SE	P-value	β	SE	P-value
Aβ_1–42	-0.31	0.16	0.065	-0.15	0.2	0.46	-0.57	0.25	0.022
Aβ_1–40	-0.28	0.18	0.13	-0.069	0.22	0.76	-0.63	0.27	0.023
Aβ ratio	-0.085	0.14	0.53	-0.12	0.16	0.46	-0.033	0.21	0.88
sAPPα	-0.18	0.2	0.37	0.067	0.24	0.78	-0.59	0.29	0.047
sAPPβ	-0.3	0.19	0.11	-0.068	0.23	0.77	-0.69	0.28	0.016
YKL-40	-0.14	0.18	0.44	0.24	0.22	0.26	-0.79	0.27	0.0036
hFABP	0.21	0.18	0.23	0.37	0.21	0.084	-0.056	0.27	0.84
T-tau	0.18	0.19	0.34	0.32	0.23	0.17	0.01	0.27	0.97
P-tau181	-0.11	0.18	0.53	-0.06	0.22	0.79	-0.18	0.26	0.5

Linear regression on INT transformed biomarker data performed between the shown groups with age, sex, and APOE ε4 status as covariates. Mutation carriers include both PTC and VNTR expansion mutation carriers. Significant P-values (P < 0.05) are shown in italics

ISSN: 1758-9193